Eli Lilly and Company (SIX: LLY.SW) Stock Competitors & Peer Comparison

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, JNJ.SW has a market cap of 535.1B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while JNJ.SW trades at CHF 222.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas JNJ.SW's P/E ratio is 25.26. In terms of profitability, LLY.SW's ROE is +0.93%, compared to JNJ.SW's ROE of +0.26%. Regarding short-term risk, LLY.SW is similarly volatile compared to JNJ.SW. This indicates similar risk in terms of short-term price fluctuations for LLY.SW.Check JNJ.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, RO.SW has a market cap of 276.4B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while RO.SW trades at CHF 352.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas RO.SW's P/E ratio is 21.14. In terms of profitability, LLY.SW's ROE is +0.93%, compared to RO.SW's ROE of +0.37%. Regarding short-term risk, LLY.SW is less volatile compared to RO.SW. This indicates lower risk in terms of short-term price fluctuations for LLY.SW.Check RO.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, ROP.SW has a market cap of 275B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while ROP.SW trades at CHF 345.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas ROP.SW's P/E ratio is 17.75. In terms of profitability, LLY.SW's ROE is +0.93%, compared to ROP.SW's ROE of +0.37%. Regarding short-term risk, LLY.SW is less volatile compared to ROP.SW. This indicates lower risk in terms of short-term price fluctuations for LLY.SW.Check ROP.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, ROG.SW has a market cap of 256.6B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while ROG.SW trades at CHF 322.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas ROG.SW's P/E ratio is 20.11. In terms of profitability, LLY.SW's ROE is +0.93%, compared to ROG.SW's ROE of +0.41%. Regarding short-term risk, LLY.SW is less volatile compared to ROG.SW. This indicates lower risk in terms of short-term price fluctuations for LLY.SW.Check ROG.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, NOVN.SW has a market cap of 213.1B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while NOVN.SW trades at CHF 112.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas NOVN.SW's P/E ratio is 16.32. In terms of profitability, LLY.SW's ROE is +0.93%, compared to NOVN.SW's ROE of +0.30%. Regarding short-term risk, LLY.SW is less volatile compared to NOVN.SW. This indicates lower risk in terms of short-term price fluctuations for LLY.SW.Check NOVN.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, GILD.SW has a market cap of 143.2B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while GILD.SW trades at CHF 115.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas GILD.SW's P/E ratio is -290.93. In terms of profitability, LLY.SW's ROE is +0.93%, compared to GILD.SW's ROE of -0.17%. Regarding short-term risk, LLY.SW is similarly volatile compared to GILD.SW. This indicates similar risk in terms of short-term price fluctuations for LLY.SW.Check GILD.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, GSK.SW has a market cap of 101.6B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while GSK.SW trades at CHF 19.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas GSK.SW's P/E ratio is 18.76. In terms of profitability, LLY.SW's ROE is +0.93%, compared to GSK.SW's ROE of +0.38%. Regarding short-term risk, LLY.SW is not fully comparable compared to GSK.SW. This indicates unavailable risk data in terms of short-term price fluctuations for LLY.SW.Check GSK.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, BMY.SW has a market cap of 87.7B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while BMY.SW trades at CHF 52.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas BMY.SW's P/E ratio is 10.13. In terms of profitability, LLY.SW's ROE is +0.93%, compared to BMY.SW's ROE of +0.45%. Regarding short-term risk, LLY.SW is similarly volatile compared to BMY.SW. This indicates similar risk in terms of short-term price fluctuations for LLY.SW.Check BMY.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, BAYN.SW has a market cap of 45.5B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while BAYN.SW trades at CHF 46.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas BAYN.SW's P/E ratio is 10.33. In terms of profitability, LLY.SW's ROE is +0.93%, compared to BAYN.SW's ROE of -0.06%. Regarding short-term risk, LLY.SW is similarly volatile compared to BAYN.SW. This indicates similar risk in terms of short-term price fluctuations for LLY.SW.Check BAYN.SW's competition here

Eli Lilly and Company (SIX: LLY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY.SW stands at 842.7B. In comparison, BIIB.SW has a market cap of 20.8B. Regarding current trading prices, LLY.SW is priced at CHF 945.00 on the SIX, while BIIB.SW trades at CHF 141.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY.SW currently has a P/E ratio of 37.54, whereas BIIB.SW's P/E ratio is 11.19. In terms of profitability, LLY.SW's ROE is +0.93%, compared to BIIB.SW's ROE of +0.05%. Regarding short-term risk, LLY.SW is similarly volatile compared to BIIB.SW. This indicates similar risk in terms of short-term price fluctuations for LLY.SW.Check BIIB.SW's competition here